BLACKSBURG, VA, Intrexon has completed a $17 million offering, raising the amount from a single investor and adding to its $128 million in prior financing.

The firm's mission is to redefine the product development cycle, reducing the time, cost, and technical risks inherent in engineering biological and cellular systems.

With over 400 patents and patent applications, Intrexon is working with key channel partners across its five divisions to deliver better products through unmatched control over living cells. With scalable engineering of rationally designed complex transgenes, Intrexon is redefining industrial synthetic biology.

Founded in 1998, Intrexon Corporation is a privately held synthetic biology company with facilities in Maryland, Virginia, North Carolina and California.